Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MLS301
- Development stage
- Preclinical
- Lead developer
- MycoMedica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MLS301 is an early-stage, low-dose psilocybin formulation under development by MycoMedica Life Sciences for the treatment of Obsessive-Compulsive Disorder (OCD). Psilocybin is a classic psychedelic tryptamine that acts as a prodrug to psilocin, which primarily targets and activates serotonin 5-HT2A and 5-HT1A receptors in the brain. By modulating serotonergic pathways, MLS301 aims to disrupt the rigid, repetitive cognitive patterns and neural circuitry associated with OCD, potentially offering rapid and sustained therapeutic relief with a low-dose paradigm designed to minimize hallucinogenic effects.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR6 (5-hydroxytryptamine receptor 6)
Beyond the preview
Go deeper on MLS301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MLS301.